Table 1 Clinical characteristics of the study population
|  | Total sample (n = 254) | HIV negative (HIV-neg) (n = 63) | HIV positive – undetectable** (HIV-U) (n = 91) | HIV positive – detectable (HIV-D) (n = 100) | p |
|---|---|---|---|---|---|
Mean age (SEM)a | 52.8 (0.75) | 53.3 (1.4) | 58.2 (1.2) | 47.7 (1.1) |  < 0.0001 |
Male sex, n (%) | 157 (61.8%) | 39 (61.9%) | 57 (62.6%) | 61 (61.0%) | 0.9732 |
Race/ethnicity, n (%) Black Hispanic White Other | 113 (44.5%) 85 (33.5%) 49 (19.3%) 7 (2.7%) | 27 (42.9%) 22 (34.9%) 12 (19.1%) 2 (3.1%) | 36 (39.6%) 30 (33.0%) 23 (25.2%) 2 (2.2%) | 50 (50.0%) 33 (33.0%) 14 (14.0%) 3 (3.0%) | 0.5991 |
APOE \(\upvarepsilon\)4, n (%)*b | 76 (30.0%) | 18 (28.6%) | 20 (22.0%) | 38 (38.4%) | 0.0460 |
APOE \(\upvarepsilon\)2, n (%)* | 47 (18.6%) | 11 (17.5%) | 17 (18.7%) | 19 (19.2%) | 0.9621 |
Median CD4 count cells/mm3 [IQR]c | NA | NA | 278 [133,503] | 74 [12,187] |  < 0.0001 |
Median log plasma HIV load [IQR]d | NA | NA | 1.69 [1.69,1.69] | 4.67 [2.80,5.53] |  < 0.0001 |
Mean duration of HIV disease in years (SEM)c | NA | NA | 18.6 (0.8) | 12.7 (0.7) |  < 0.0001 |
Frontal parenchymal amyloid deposition, n (%)e | 78 (30.7%) | 25 (39.7%) | 34 (37.4%) | 19 (19.0%) | 0.0026 |
Moderate to severe frontal amyloid deposition, n (%)e | 28 (11.0%) | 9 (14.3%) | 12 (13.2%) | 7 (7.0%) | 0.0120 |
Neuronal ptau in frontal cortex | 58 (22.8%) | 17 (27.0%) | 22 (24.2%) | 19 (19.0%) | 0.4623 |
Hypertensione | 118 (46.5%) | 35 (55.6%) | 53 (58.2%) | 30 (30.0%) | 0.0001 |
Diabetes Mellitusf | 68 (26.8%) | 26 (41.3%) | 28 (30.8%) | 14 (14.0%) | 0.0004 |
Hepatitis (B or C)g | 166 (65.4%) | 31 (49.2%) | 71 (78.0%) | 64 (64.0%) | 0.0010 |